03/03/2013

ImmunoSite Technologies Expands into New Spacious Facility in Miramar

Press Release, February 28, 2013 ImmunoSite Technologies, LLC (IST), a provider of automation, design and customization of complex biological assays to biotechnology and pharmaceutical industries worldwide, announced its relocation to a newly expanded facility at 2831 Corporate Way in Miramar.  With the expansion, the company will be retaining its current 6 employees, making a capital [...]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


01/18/2013

2013 SLAS 2nd Annual Conference & Exhibition

Executives, Engineers, and Scientists from ImmunoSite Technologies attended the Annual 2013 SLAS meeting in Orlando, Florida and brought back some of the latest technologies to integrate into new automated solutions for biological assay automation that will enhance their client’s productivity even more! Call IST to discuss your automation needs at (888) 770-4478 Share this:

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


05/07/2012

Assay Automation Ability - Lyophilized reagents for in vitro whole blood assays

Tags: , , , , , , , , ,

The need to implement robust biomarkers in clinical trials has never been greater, and such efforts can be easily compromised by reagent instability or simple human error during assay set-up. Many biotechnology and pharmaceutical companies are introducing efforts to conduct biomarker studies under more rigorous settings, and the use of plates or tubes pre-loaded with stimulation or staining reagents could be of value for studies that involve flow cytometry.
The value of this approach is that it lends itself to assay automation easily and safeguards against omission or erroneous addition of bulk liquid formulations of PMA and ionomycin to the reaction vessel (i.e., plate or tube) and also lends itself to extended stability/shelf-life of these reagents. On the basis of this initial success, we plan to expand our evaluation of lyophilized reagents so that they can be incorporated into our clinical biomarker campaigns as appropriate.

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


11/01/2011

ImmunoSite Technologies Allies with Goodwin Biotechnology Increasing Capabilities

Tags: , , , , ,

Working together, ImmunoSite Technologies and Goodwin Biotechnology companies offer enhanced abilities to develop, test and manufacture biopharmaceuticals

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


10/18/2011

ImmunoSite Technologies Aides in Curriculum Development for Employ Florida Banner Center

Tags:

Cell Culture Course helps Floridians enter, remain and advance in the workforce Full release click here. Fort Lauderdale, Fla. – October 18, 2011 – ImmunoSite Technologies (IST), LLC, a leading provider of immune monitoring services, has helped develop a Cell Culture Workshop that will be offered for the first time October 27 and 28 at [...]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


09/27/2011

ImmunoSite Technologies Allies with Immudex for More Effective T Cell Response Monitoring

Tags: , , , , , , , , , ,

Working together, companies offer enhanced abilities to monitor immunotherapy response in vaccine and drug studies.

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


04/03/2011

ImmunoSite Technologies Provides Particle Testing Services to Beckman Coulter Customers

Tags: , , , , , , ,

IST employs a wide range of particle testing technologies

Leading provider of particle testing services now receives referrals of customers seeking particle characterization services from Beckman Coulter, Inc. Fort Lauderdale, Fla. – April 3, 2011 – ImmunoSite Technologies, LLC, a leading provider of immune monitoring services, is now receiving direct customer referrals for particle testing services from Beckman Coulter, Inc. as part of a [...]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading